Humacyte, Inc. HUMA
We take great care to ensure that the data presented and summarized in this overview for Humacyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HUMA
View all-
Black Rock Inc. New York, NY7.14MShares$38.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$25.5 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$15.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$10 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.6MShares$8.62 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.24MShares$6.7 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.14MShares$6.16 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY762KShares$4.1 Million0.0% of portfolio
-
Voloridge Investment Management, LLC Jupiter, FL687KShares$3.7 Million0.01% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA654KShares$3.53 Million0.0% of portfolio
Latest Institutional Activity in HUMA
Top Purchases
Top Sells
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Insider Transactions at HUMA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 13
2024
|
Charles Bruce Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+33.33%
|
$4,800
$4.09 P/Share
|
Sep 10
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
288,674
-8.2%
|
$1,443,370
$5.23 P/Share
|
Sep 10
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
288,674
-8.2%
|
$1,443,370
$5.23 P/Share
|
Sep 10
2024
|
Kathleen Sebelius Director |
SELL
Open market or private sale
|
Direct |
5,182
-5.95%
|
$25,910
$5.4 P/Share
|
Sep 10
2024
|
Kathleen Sebelius Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+7.41%
|
$21,000
$3.85 P/Share
|
Sep 09
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
157,704
-4.29%
|
$788,520
$5.42 P/Share
|
Sep 09
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
157,704
-4.29%
|
$788,520
$5.42 P/Share
|
Aug 29
2024
|
Laura E Niklason President, CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,222
+0.5%
|
$7,332
$6.54 P/Share
|
Aug 29
2024
|
Brady W Dougan Director |
BUY
Open market or private purchase
|
Indirect |
1,222
+0.5%
|
$7,332
$6.54 P/Share
|
Aug 29
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
352,112
-8.74%
|
$2,112,672
$6.35 P/Share
|
Aug 29
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
352,112
-8.74%
|
$2,112,672
$6.35 P/Share
|
Aug 28
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
277,090
-6.43%
|
$1,662,540
$6.47 P/Share
|
Aug 28
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
277,090
-6.43%
|
$1,662,540
$6.47 P/Share
|
Aug 27
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
252,676
-5.54%
|
$1,516,056
$6.71 P/Share
|
Aug 27
2024
|
Dale A. Sander CFO and Chief Corp. Deve. Off. |
SELL
Open market or private sale
|
Direct |
39,389
-95.17%
|
$236,334
$6.68 P/Share
|
Aug 27
2024
|
Dale A. Sander CFO and Chief Corp. Deve. Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
39,389
+48.76%
|
$78,778
$2.56 P/Share
|
Aug 27
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
252,676
-5.54%
|
$1,516,056
$6.71 P/Share
|
Aug 15
2024
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
3,100
+20.06%
|
$18,600
$6.29 P/Share
|
Jun 14
2024
|
Kathleen Sebelius Director |
BUY
Exercise of conversion of derivative security
|
Direct |
39,389
+50.0%
|
$78,778
$2.56 P/Share
|
Jun 12
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
271,518
-5.62%
|
$1,900,626
$7.3 P/Share
|
Last 12 Months Summary
Open market or private purchase | 122K shares |
---|---|
Exercise of conversion of derivative security | 222K shares |
Open market or private sale | 6.16M shares |
---|